Literature DB >> 15084746

Lactosylceramide recruits PKCalpha/epsilon and phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to endothelial cells.

NanLing Gong1, Heming Wei, Sanaul Haq Chowdhury, Subroto Chatterjee.   

Abstract

Despite the importance of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in the adhesion and diapedesis of monocytes/lymphocytes, little is known about the mechanisms by which it is regulated. We explored the role of a glycosphingolipid, lactosylceramide (LacCer), in modulating PECAM-1 expression and cell adhesion in human monocytes. We observed that LacCer specifically exerted a time-dependent increase in PECAM-1 expression in U-937 cells. Maximal increase in PECAM-1 protein occurred after incubation with LacCer for 60 min. LacCer activated PKCalpha and -epsilon by translocating them from cytosol to membrane. This was accompanied by the activation of phospholipase A(2) (PLA(2)) and the increase of cell adhesion, which were abrogated by chelerythrine chloride, 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide and 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (GO 6976) (PKC inhibitors). Similarly, bromoenol lactone (a Ca(2+)-independent PLA(2) inhibitor) and methyl arachidonyl fluorophosphonate (an inhibitor of cytosolic PLA(2) and Ca(2+)-independent PLA(2)) inhibited LacCer-induced PLA(2) activity. Bromophenacyl bromide (a PLA(2) inhibitor) abrogated LacCer-induced PECAM-1 expression, and this was bypassed by arachidonic acid. Furthermore, the arachidonate-induced up-regulation of PECAM-1 was abrogated by indomethacin [a cyclooxygenase (COX)-1 and -2 inhibitor] or N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide (a COX-2 inhibitor) but not nordihydroguaiaretic acid (a lipoxygenase inhibitor). In sum, PKCalpha/epsilon are the primary targets for the activation of LacCer. Downstream activation of intracellular Ca(2+)-independent PLA(2) and/or cytosolic PLA(2) results in the production of arachidonic acid, which in turn serves as a precursor for prostaglandins that subsequently stimulate PECAM-1 expression and cell adhesion. These findings may be relevant in explaining the role of LacCer in the regulation of PECAM-1 and related pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084746      PMCID: PMC404072          DOI: 10.1073/pnas.0308684101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane.

Authors:  M W Wakelin; M J Sanz; A Dewar; S M Albelda; S W Larkin; N Boughton-Smith; T J Williams; S Nourshargh
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

2.  Chelerythrine is a potent and specific inhibitor of protein kinase C.

Authors:  J M Herbert; J M Augereau; J Gleye; J P Maffrand
Journal:  Biochem Biophys Res Commun       Date:  1990-11-15       Impact factor: 3.575

3.  Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues.

Authors:  S B Chatterjee; S Dey; W Y Shi; K Thomas; G M Hutchins
Journal:  Glycobiology       Date:  1997-02       Impact factor: 4.313

4.  Characterization of the human platelet/endothelial cell adhesion molecule-1 promoter: identification of a GATA-2 binding element required for optimal transcriptional activity.

Authors:  R J Gumina; N E Kirschbaum; K Piotrowski; P J Newman
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

5.  Molecular characterization and functional analysis of the leukocyte surface protein CD31.

Authors:  H Stockinger; S J Gadd; R Eher; O Majdic; W Schreiber; W Kasinrerk; B Strass; E Schnabl; W Knapp
Journal:  J Immunol       Date:  1990-12-01       Impact factor: 5.422

6.  Organization of the gene for human platelet/endothelial cell adhesion molecule-1 shows alternatively spliced isoforms and a functionally complex cytoplasmic domain.

Authors:  N E Kirschbaum; R J Gumina; P J Newman
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

7.  Lactosylceramide stimulates aortic smooth muscle cell proliferation.

Authors:  S Chatterjee
Journal:  Biochem Biophys Res Commun       Date:  1991-12-16       Impact factor: 3.575

8.  Platelet endothelial cell adhesion molecule, PECAM-1, modulates cell migration.

Authors:  L A Schimmenti; H C Yan; J A Madri; S M Albelda
Journal:  J Cell Physiol       Date:  1992-11       Impact factor: 6.384

9.  Sphingosine 1-phosphate generated in the endoplasmic reticulum membrane activates release of stored calcium.

Authors:  T K Ghosh; J Bian; D L Gill
Journal:  J Biol Chem       Date:  1994-09-09       Impact factor: 5.157

10.  Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1.

Authors:  F Liao; H K Huynh; A Eiroa; T Greene; E Polizzi; W A Muller
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  27 in total

1.  Lactosylceramide interacts with and activates cytosolic phospholipase A2α.

Authors:  Hiroyuki Nakamura; Yuta Moriyama; Tomohiko Makiyama; Shunsuke Emori; Hisahiro Yamashita; Risa Yamazaki; Toshihiko Murayama
Journal:  J Biol Chem       Date:  2013-06-25       Impact factor: 5.157

2.  Lactosylceramide: lateral interactions with cholesterol.

Authors:  Xiuhong Zhai; Xin-Min Li; Maureen M Momsen; Howard L Brockman; Rhoderick E Brown
Journal:  Biophys J       Date:  2006-07-07       Impact factor: 4.033

3.  Interictal, circulating sphingolipids in women with episodic migraine: A case-control study.

Authors:  B Lee Peterlin; Michelle M Mielke; Alex M Dickens; Subroto Chatterjee; Paul Dash; Guillermo Alexander; Rebeca V A Vieira; Veera Venkata Ratnam Bandaru; Joelle M Dorskind; Gretchen E Tietjen; Norman H Haughey
Journal:  Neurology       Date:  2015-09-09       Impact factor: 9.910

4.  Inhibition of glycosphingolipid synthesis ameliorates atherosclerosis and arterial stiffness in apolipoprotein E-/- mice and rabbits fed a high-fat and -cholesterol diet.

Authors:  Subroto Chatterjee; Djahida Bedja; Sumita Mishra; Christine Amuzie; Alberto Avolio; David A Kass; Dan Berkowitz; Mark Renehan
Journal:  Circulation       Date:  2014-04-07       Impact factor: 29.690

5.  Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor.

Authors:  S Mishra; D Bedja; C Amuzie; C A Foss; M G Pomper; R Bhattacharya; K J Yarema; S Chatterjee
Journal:  Biomaterials       Date:  2015-06-03       Impact factor: 12.479

6.  VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo.

Authors:  Antonina Kolmakova; Mohanraj Rajesh; David Zang; Roberto Pili; Subroto Chatterjee
Journal:  Glycoconj J       Date:  2009-02-14       Impact factor: 2.916

7.  Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.

Authors:  Lior Mayo; Sunia A Trauger; Manon Blain; Meghan Nadeau; Bonny Patel; Jorge I Alvarez; Ivan D Mascanfroni; Ada Yeste; Pia Kivisäkk; Keith Kallas; Benjamin Ellezam; Rohit Bakshi; Alexandre Prat; Jack P Antel; Howard L Weiner; Francisco J Quintana
Journal:  Nat Med       Date:  2014-09-14       Impact factor: 53.440

8.  Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2.

Authors:  Corine Martineau; Roy Pascal Naja; Abdallah Husseini; Bachar Hamade; Martin Kaufmann; Omar Akhouayri; Alice Arabian; Glenville Jones; René St-Arnaud
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

Review 9.  Protein kinase Calpha: disease regulator and therapeutic target.

Authors:  Olga Konopatskaya; Alastair W Poole
Journal:  Trends Pharmacol Sci       Date:  2009-12-05       Impact factor: 14.819

10.  Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition.

Authors:  Elias N Glaros; Woojin S Kim; Brett Garner
Journal:  Clin Sci (Lond)       Date:  2010-03-30       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.